Author: admin

Sir Ivan Drops “Love Is The Piece”: A Modern Peace Anthem for a World in Crisis

Photo Courtesy: Sir Ivan

Miami, FL – Recording artist and philanthropist Sir Ivan has released a new single titled “Love Is The Piece,” presenting what he describes as a modern peace anthem during a period of rising global tension and social division.

Sir Ivan, also known worldwide as “Peaceman,” has built a career centered on themes of universal love, unity, and nonviolence within contemporary electronic music. His latest release continues that mission, blending uplifting electronic production with lyrics focused on empathy and shared humanity.

Built around the chorus, “Love is the piece we need for peace,” the song addresses ongoing global conflict and civil unrest. The lyrics emphasize that peace begins within individuals and transcends religious, national, and cultural boundaries. In one verse, Sir Ivan sings: “It goes beyond Christians, Muslims, and Jews… The answer’s not blowin’ in the wind / ’Cause our hearts hold the one solution within.”

The release reflects Sir Ivan’s long-standing artistic direction. His recording career began in 2001 with a high-energy dance version of John Lennon’s “Imagine,” released on Tommy Boy Records. The track entered the Billboard Dance/Club Play charts and marked the first official dance reinterpretation of a Lennon or Beatles ballad. Over the following years, he achieved multiple Top 10 placements on Billboard and the UK’s Music Week charts.

Sir Ivan has collaborated with a range of respected figures in electronic and pop music, including Grammy Award-winning producers Jason Evigan, Peter Rafelson, Tracy Young, Midi Mafia, and Omar Okram. He has also worked with Paul Oakenfold, Markus Schulz, and Jeff Timmons of 98 Degrees, who produced the original mix of “Love Is The Piece.”

The new single builds on recent projects, including his collaboration with trance artist Markus Schulz on a reimagined version of “Turn! Turn! Turn!” released through Coldharbour Recordings. The project received coverage from electronic music publications such as EDM.com and We Rave You, highlighting Sir Ivan’s continued presence within the global dance music community.

Beyond music, Sir Ivan is the founder of The Peaceman Foundation, through which he has donated more than $500,000 to initiatives supporting anti-bullying efforts, LGBTQ+ youth, PTSD research, and victims of violence. In 2018, the City of Miami Beach officially proclaimed December 12 as “Sir Ivan Wilzig Day” in recognition of his advocacy against bullying and violence.

Born Ivan Wilzig in Clifton, New Jersey, he earned a bachelor’s degree in European Intellectual History from the University of Pennsylvania and later a law degree from the Benjamin N. Cardozo School of Law. After more than two decades in commercial banking, including service on the board of The Trust Company of New Jersey, he transitioned fully into music, adopting the name Sir Ivan and dedicating his work to peace-centered themes.

“Love Is The Piece” represents what Sir Ivan describes as one of his most personal works to date. All proceeds from the release are dedicated to supporting PTSD research and communities affected by trauma.

With this latest single, Sir Ivan continues his long-standing effort to use electronic music as a platform for advocacy, positioning dance culture not only as entertainment but also as a vehicle for connection and reflection in a divided world.

Photo Courtesy: Sir Ivan

About Sir Ivan

Sir Ivan, also known as Peaceman, is a Billboard Top 10 recording artist, philanthropist, and peace advocate. A former commercial banker and law graduate, he transitioned into music to promote messages of universal love, unity, and nonviolence through electronic dance music. He is the founder of The Peaceman Foundation and has donated more than $500,000 to causes supporting anti-bullying initiatives, LGBTQ+ youth, PTSD research, and victims of violence. Sir Ivan continues to record, collaborate, and advocate within the global electronic music community.

Media Contact
Company Name: MCPR
Contact Person: Steven Bartolo
Email: Send Email
Phone: +448006894723
Country: United Kingdom
Website: https://www.mattcaldwell.co.uk/

BrightStar Care of Las Vegas and Henderson Receives Prestigious Leader in Experience Home Care Award

Las Vegas, NV – BrightStar Care of Las Vegas and Henderson has earned national recognition as one of the premier home care providers in the country, and was awarded the Best of Home Care – Leader in Experience distinction from Home Care Pulse. This elite status is reserved for a limited number of home care agencies across the United States and showcases the Las Vegas team’s consistent dedication to outstanding client and caregiver experiences.

Home Care Pulse determines the Leader in Experience award using ongoing, third-party surveys completed by clients and caregivers throughout the year. Their feedback highlights BrightStar Care of Las Vegas and Henderson’s ability to combine compassionate support with dependable service, clear communication, and strong trust. The agency’s Registered Nurse–directed model means every individual receives a customized care plan that can include skilled nursing, personal care, companion services, and condition-specific support delivered safely in the home. Access the following link to learn more about our services: https://www.brightstarcare.com/locations/henderson/services/in-home-care/

Recognized for Both Client and Caregiver Satisfaction

BrightStar Care of Las Vegas and Henderson has also achieved the Best of Home Care – Provider of Choice and Best of Home Care – Employer of Choice awards from Home Care Pulse, underscoring excellence on both sides of the care relationship. These honors reinforce the agency’s standing as a highly trusted option for families seeking home care and as a strong employer for professional caregivers and nurses in the Las Vegas area.

The Provider of Choice recognition reflects top-tier scores from clients in areas such as reliability, professionalism, communication, and overall quality of care. The Employer of Choice award signals that caregivers and nurses feel valued and supported, thanks to competitive pay, robust training, and a leadership team that prioritizes their safety, growth, and work–life balance.

Elevating Home Care for Las Vegas Families

By blending compassionate service with clinical oversight, BrightStar Care of Las Vegas and Henderson continues to raise the bar for ‘A Higher Standard’ for home care in the community. RN-led care planning, thorough employee screening, ongoing education, and 24/7 availability help ensure that clients receive the right level of care—whether they need short visits for support with daily tasks or continuous, complex care at home.

To learn more about BrightStar Care of Las Vegas and Henderson and its award‑winning home care services, visit https://www.brightstarcare.com/locations/las-vegas-w/ or call 702‑982‑2273.

Media Contact
Company Name: BrightStar Care of Las Vegas and Henderson
Contact Person: Becky Torrez
Email: Send Email
Phone: (702) 982-2273
Country: United States
Website: https://www.brightstarcare.com/locations/henderson/contact-us/

Z Med Clinic Expands Medically Supervised Healthy Living Programs Across Texas

HOUSTON, TX – As the demand for professional, science-based health solutions continues to rise, Z Med Clinic is proud to announce the expansion and enhancement of its specialized medical weight loss services. Operating as a premier weight loss clinic in HOUSTON TX, the facility is dedicated to helping patients achieve sustainable health goals through personalized medical supervision and innovative treatment protocols.

In an era where fad diets and over the counter supplements often lead to disappointing results, Z Med Clinic distinguishes itself by offering a structured, clinical approach. The clinic understands that weight management is not a one size that fits all journeys. Instead, it requires a deep understanding of metabolic health, hormonal balance, and individual lifestyle factors. By focusing on the biological roots of weight gain, the TX medical weight loss clinic provides patients with the tools they need to lose weight safely and keep it off long term.

The comprehensive programs at Z Med Clinic in Houston, Texas, are designed to bridge the gap between traditional primary care and specialized bariatric services. Each patient begins their journey with an in-depth consultation and health assessment. This allows the medical team to identify underlying concerns such as insulin resistance, thyroid imbalances, vitamin deficiencies, or metabolic dysfunction that may have hindered previous weight loss attempts.

As a leading TX medical weight loss clinic, Z Med Clinic offers advanced treatment options, including GLP-1 for weight loss, FDA-approved weight loss medications, customized nutritional counseling, and lipotropic injections designed to boost metabolism and energy levels. By integrating these medical interventions with lifestyle modifications, the clinic ensures patients experience a comprehensive and sustainable transformation.

One of the key advantages of choosing a professional weight loss clinic in TX is accountability. Regular check-ins allow providers to monitor progress, track body composition changes, and offer ongoing medical and emotional support. This consistent clinical oversight is what sets Z Med Clinic apart from self-directed or online programs.

About Z Med Clinic

Z Med Clinic is a multi-specialty medical facility offering family medicine, aesthetic services, and advanced weight management programs. The clinic provides patient-centered care across multiple Texas locations, including Houston.

For more information about the services offered or to schedule a consultation, please visit the official website: https://www.zmedclinic.com/services/weight-loss-clinic/

Media Contact
Company Name: Z Med Clinic and Med Spa
Email: Send Email
Country: United States
Website: https://www.zmedclinics.com

BrightStar Care of Peabody/Danvers/North Shore Earns 2026 Best of Home Care® Awards

Danvers, Mass. – BrightStar Care of Peabody/Danvers/North Shore has earned three prestigious 2026 Best of Home Care® awards from Home Care Pulse: Leader in Experience, Provider of Choice, and Employer of Choice. Based on confidential feedback from clients and caregivers, these three awards place the local agency among the top tier of home care providers nationwide.​

The Best of Home Care® – Leader in Experience award is the highest recognition a home care agency can receive from Home Care Pulse, signifying best-in-class satisfaction ratings from both clients and caregivers. To earn this award, an agency must also qualify as both a Provider of Choice and Employer of Choice, demonstrating excellence across a broad range of quality and experience measures.​

The Provider of Choice award is given to agencies that maintain strong client satisfaction in key areas, including reliability, communication, compassion, and overall care quality. The Employer of Choice award honors organizations with outstanding caregiver satisfaction, emphasizing a supportive work environment, meaningful training opportunities, and a culture where team members feel respected and empowered.

As part of the Home Care Pulse program, a portion of BrightStar Care of Peabody / Danvers / North Shore’s clients and caregivers are interviewed each month by an independent third party, ensuring unbiased insight into their experience. Over a 12‑month period, the agency has received consistently high ratings across areas such as caregiver training, communication, scheduling, and client–caregiver compatibility, demonstrating an ongoing commitment to continuous improvement.​

BrightStar Care of Peabody / Danvers / North Shore provides a full range of in‑home care services – including personal care, companion care, and skilled nursing – for children, adults, and seniors throughout the North Shore communities. Each client’s care is overseen by a Registered Nurse, supporting individualized plans of care and coordination with families and healthcare providers.

Learn more about our care team: https://www.brightstarcare.com/locations/peabody-danvers-northshore/about-us/our-care-team/

Media Contact
Company Name: BrightStar Care of Peabody / Danvers / North Shore
Contact Person: Melissa Janicke
Email: Send Email
Phone: (978) 278-3320
Country: United States
Website: https://www.brightstarcare.com/locations/peabody-danvers-northshore/

Metastatic Colorectal Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Colorectal Cancer pipeline constitutes 150+ key companies continuously working towards developing 180+ Metastatic Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Metastatic Colorectal Cancer Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Colorectal Cancer Market.

 

The Metastatic Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Get a Free Sample PDF Report to know more about Metastatic Colorectal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight

 

Some of the key takeaways from the Metastatic Colorectal Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Metastatic Colorectal Cancer treatment therapies with a considerable amount of success over the years.

  • Metastatic Colorectal Cancer companies working in the treatment market are Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Genor Biopharma, Novartis Pharmaceutical, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmaceuti cals Co., Ltd, Amgen, G1 Therapeutic s, Inc., and others, are developing therapies for the Metastatic Colorectal Cancer treatment

  • Emerging Metastatic Colorectal Cancer therapies in the different phases of clinical trials are- 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Lumakras (sotorasib), Trilaciclib, and others are expected to have a significant impact on the Metastatic Colorectal Cancer market in the coming years.

  • In February 2026, The U.S. Food and Drug Administration has granted full approval to BRAFTOVI (encorafenib) for use in combination with cetuximab and fluorouracil-based chemotherapy in adult patients with metastatic colorectal cancer (mCRC) carrying a BRAF V600E mutation, as identified through an FDA-authorized diagnostic test. This approval is supported by findings from the global Phase 3 BREAKWATER study. Earlier, on February 17, 2026, Pfizer reported positive topline data from Cohort 3 of the BREAKWATER trial, which assessed BRAFTOVI in combination with cetuximab and FOLFIRI as a first-line treatment. The combination regimen demonstrated improved progression-free survival (PFS) compared with FOLFIRI with or without bevacizumab, and overall survival results indicated a clinically meaningful extension, reported as a descriptive endpoint.

  • In February 2026, Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI (encorafenib) for use in combination with cetuximab, marketed as ERBITUX, and fluorouracil-based chemotherapy. The regimen is indicated for adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. The approval is supported by data from the global Phase 3 BREAKWATER trial (NCT04607421).

  • In August 2025, The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ABT-301, authorizing the launch of a Phase 1/2 clinical trial evaluating the therapy in combination with Tevimbra (tislelizumab) and Avastin (bevacizumab) for the treatment of patients with metastatic colorectal cancer. The announcement was made by Anbogen Therapeutics, the clinical-stage biotechnology company developing ABT-301, in a recent press release.

  • In April 2025, Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotech firm focused on PLK1 inhibition to create innovative cancer treatments, has announced that patient enrollment is now complete for its ongoing Phase 2 CRDF-004 trial. The study is assessing the efficacy of onvansertib in combination with standard-of-care therapy for treating first-line RAS-mutated metastatic colorectal cancer (mCRC).

  • In February 2025, Pfizer’s combination therapy for metastatic colorectal cancer (mCRC) achieved one of its primary goals significantly improving progression-free survival (PFS) in a Phase III clinical trial, strengthening the case for full regulatory approval. The active-controlled, open-label BREAKWATER study (NCT05217446) assessed a regimen combining Pfizer’s Braftovi (encorafenib), Eli Lilly’s Erbitux (cetuximab), and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin). The therapy was evaluated in previously untreated mCRC patients with a BRAF V600E mutation and successfully met one of its dual primary endpoints by demonstrating improved PFS.

  • In November 2024, Tizona Therapeutics has broadened its ongoing Phase Ib clinical trial of TTX-080, a novel antibody targeting human leukocyte antigen-G (HLA-G), to include patients with biomarker-defined metastatic colorectal cancer (mCRC).

  • In September 2024, FRUZAQLA® (fruquintinib) is a kinase inhibitor approved for the treatment of adults with metastatic colorectal cancer (mCRC). This innovative oral treatment is designed for once-daily use, providing a non-chemotherapy alternative for patients who have previously received specific anti-cancer therapies. These may include chemotherapy regimens based on fluoropyrimidine, oxaliplatin, and irinotecan, as well as anti-vascular endothelial growth factor (VEGF) therapy.

  • In January 2024, Bold Therapeutics, a biopharmaceutical company in the clinical stage, shared favorable results from Phase 2 trials assessing the safety and effectiveness of BOLD-100 in combination with FOLFOX. These trials focused on patients with advanced metastatic colorectal cancer who had previously received treatment with FOLFOX/CAPOX. The findings were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium held from January 18 to 20, 2024.

 

Metastatic Colorectal Cancer Overview

Metastatic colorectal cancer refers to a stage of colorectal cancer where cancer cells have spread from the primary site (the colon or rectum) to other parts of the body, forming secondary tumors. Colorectal cancer typically starts as a growth of tissue (polyp) in the lining of the colon or rectum and may progress through various stages, with metastatic or advanced stages indicating a more widespread and severe condition.

 

Explore the latest Metastatic Colorectal Cancer pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Metastatic Colorectal Cancer Clinical Trials

 

Emerging Metastatic Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:

  • 188RNL-BAM: Plus Therapeutics

  • PCS11T: Processa Pharmaceutic als

  • HLX13: Shanghai Henlius Biotech

  • Geptanolimab: Genor Biopharma

  • HDM201: Novartis Pharmaceutical

  • TP-1454: Sumitomo Pharma Oncology

  • NT219: Purple Biotech Ltd.

  • NKTR-255: Nektar Therapeutics

  • Evorpacept (ALX148): ALX Oncology Inc.

  • CPGJ 602: Sunshine Guojian Pharmaceutic al

  • Trastuzumab deruxtecan: Daiichi Sanky

  • GRT-C901: Gritstone Bio, Inc

  • SHR-1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd

  • Lumakras (sotorasib): Amgen

  • Trilaciclib: G1 Therapeutic s, Inc.

 

Metastatic Colorectal Cancer Route of Administration

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Metastatic Colorectal Cancer Molecule Type

Metastatic Colorectal Cancer Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

 

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

  • Metastatic Colorectal Cancer Assessment by Product Type

  • Metastatic Colorectal Cancer By Stage and Product Type

  • Metastatic Colorectal Cancer Assessment by Route of Administration

  • Metastatic Colorectal Cancer By Stage and Route of Administration

  • Metastatic Colorectal Cancer Assessment by Molecule Type

  • Metastatic Colorectal Cancer by Stage and Molecule Type

 

DelveInsight’s Metastatic Colorectal Cancer Report covers around 180+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Metastatic Colorectal Cancer product details are provided in the report. Download the Metastatic Colorectal Cancer pipeline report to learn more about the emerging Metastatic Colorectal Cancer therapies

 

Some of the key companies in the Metastatic Colorectal Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Colorectal Cancer are – Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, and others.

 

Metastatic Colorectal Cancer Pipeline Analysis:

The Metastatic Colorectal Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.

  • Metastatic Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Metastatic Colorectal Cancer drugs and therapies

 

Metastatic Colorectal Cancer Pipeline Market Drivers

  • Emergence of targeted therapies for mCRC treatment, technical Advancement in molecular subtyping of CRC tumors, increase in product development activities are some of the important factors that are fueling the Metastatic Colorectal Cancer Market.

 

Metastatic Colorectal Cancer Pipeline Market Barriers

  • However, limitations in understanding secondary resistance, challenges related to precision oncology in mCRC management and other factors are creating obstacles in the Metastatic Colorectal Cancer Market growth.

 

Scope of Metastatic Colorectal Cancer Pipeline Drug Insight

  • Coverage: Global

  • Key Metastatic Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Genor Biopharma, Novartis Pharmaceutical, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmaceuti cals Co., Ltd, Amgen, G1 Therapeutic s, Inc., and others

  • Key Metastatic Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Lumakras (sotorasib), Trilaciclib, and others

  • Metastatic Colorectal Cancer Therapeutic Assessment: Metastatic Colorectal Cancer current marketed and Metastatic Colorectal Cancer emerging therapies

  • Metastatic Colorectal Cancer Market Dynamics: Metastatic Colorectal Cancer market drivers and Metastatic Colorectal Cancer market barriers

 

Request for Sample PDF Report for Metastatic Colorectal Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Metastatic Colorectal Cancer Report Introduction

2. Metastatic Colorectal Cancer Executive Summary

3. Metastatic Colorectal Cancer Overview

4. Metastatic Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Colorectal Cancer Pipeline Therapeutics

6. Metastatic Colorectal Cancer Late Stage Products (Phase II/III)

7. Metastatic Colorectal Cancer Mid Stage Products (Phase II)

8. Metastatic Colorectal Cancer Early Stage Products (Phase I)

9. Metastatic Colorectal Cancer Preclinical Stage Products

10. Metastatic Colorectal Cancer Therapeutics Assessment

11. Metastatic Colorectal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Colorectal Cancer Key Companies

14. Metastatic Colorectal Cancer Key Products

15. Metastatic Colorectal Cancer Unmet Needs

16 . Metastatic Colorectal Cancer Market Drivers and Barriers

17. Metastatic Colorectal Cancer Future Perspectives and Conclusion

18. Metastatic Colorectal Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio

High Protein Meal Plan Vancouver: 2 Guys With Knives Delivers Structured Nutrition for Performance

2 Guys With Knives offers comprehensive high protein meal plans across Metro Vancouver, providing structured nutrition with 150+ grams of daily protein through chef-prepared meals designed to support muscle development, athletic performance, and body composition goals.

VANCOUVER, BC – 2 Guys With Knives continues to serve Vancouver’s fitness and health-conscious community with its high protein meal plan, delivering structured nutrition designed to support muscle growth, athletic performance, and optimal body composition. The meal prep Vancouver service combines culinary expertise with fitness nutrition science to create convenient, delicious solutions for individuals committed to their training and wellness goals.

The high protein meal plan provides a comprehensive nutritional framework delivering 150+ grams of protein daily across multiple meals and snacks. This protein distribution aligns with sports nutrition recommendations for individuals engaged in resistance training, endurance sports, or body composition transformation. Each meal is carefully balanced to provide the protein density required for muscle protein synthesis while incorporating appropriate amounts of carbohydrates and fats to support overall health and performance.

Available in both 5-day and 7-day configurations, the meal plans accommodate different lifestyle patterns and preferences. The 5-day option covers weekday nutrition needs, providing structure during the work week when time constraints and decision fatigue often compromise nutritional consistency. The 7-day plan delivers complete weekly coverage including weekends, ensuring uninterrupted nutritional support for those pursuing aggressive training programs.

Chef Sergio Pereira’s culinary background brings an essential dimension to the meal plan that separates it from typical fitness nutrition. Rather than viewing food purely as fuel, he approaches each recipe as an opportunity to deliver both nutritional value and genuine eating enjoyment. This philosophy proves critical for long-term adherence, as sustainable nutrition plans must be satisfying enough that people actually want to follow them consistently.

The meal prep Vancouver operation reflects this commitment to quality in its ingredient selection and preparation methods. High-quality protein sources including chicken breast, turkey, lean beef, fish, and eggs form the foundation of the menu. Complex carbohydrates from rice, quinoa, sweet potatoes, and whole grains provide sustained energy for training and recovery. Healthy fats from sources like avocado, nuts, and olive oil support hormone production and overall health.

Patrick Carr’s fitness expertise ensures that the macronutrient composition of each meal supports the physiological demands of training and recovery. His understanding of how different training phases require adjusted nutritional approaches allows the meal plans to serve diverse goals, from muscle building phases requiring caloric surplus to cutting phases requiring deficit while preserving muscle mass.

Each meal arrives ready to eat with minimal preparation required. Customers simply reheat meals in the microwave for 2-4 minutes, making proper nutrition accessible even during the busiest days. This convenience eliminates common excuses for poor food choices and removes the barrier of cooking skill or time availability.

The MAP-sealed packaging technology extends meal freshness up to seven days without preservatives, providing flexibility in consumption timing while maintaining food safety and quality. Clear nutritional labeling on each container enables precise tracking for those monitoring macronutrient intake.

Most meals in the high protein meal plan are gluten-free except for house wraps, addressing common dietary sensitivities while maintaining the protein density and nutritional quality required for fitness goals. This inclusive approach ensures that individuals with gluten sensitivities or celiac disease can access convenient, high-protein nutrition without compromise.

Delivery coverage spans Metro Vancouver including Vancouver, Burnaby, Coquitlam, Surrey, North Vancouver, Richmond, Langley, White Rock, Mission, West Vancouver, and Port Moody. The refrigerated delivery system maintains proper temperature control throughout the logistics chain, ensuring meals arrive fresh and safe for consumption.

The structured nature of the meal plan provides significant psychological benefits beyond nutritional optimization. Having meals planned and prepared eliminates the daily decision-making burden around food choices, freeing mental bandwidth for other priorities. This structure proves especially valuable during periods of high stress when willpower becomes depleted.

Customer feedback consistently emphasizes how the meal plans enable consistency, widely recognized as the most critical factor in achieving fitness results. While individual meals matter, the cumulative effect of consistent, appropriate nutrition over weeks and months drives meaningful physique and performance changes.

2 Guys With Knives has built its reputation on reliability, quality, and results. The company’s growth since its 2013 founding reflects Vancouver’s increasing recognition that convenient, high-quality nutrition support represents a valuable investment in health and fitness outcomes.

For more information, visit https://2guyswithknives.com/our-meal-plans/

ABOUT 2 GUYS WITH KNIVES

2 Guys With Knives is a Vancouver-based meal prep delivery service founded in 2013 by Chef Sergio Pereira and fitness expert Patrick Carr. The company delivers chef-prepared, macro-balanced meals throughout Metro Vancouver, specializing in high protein meal plans, weight loss programs, and customizable nutrition solutions designed to support fitness, performance, and wellness goals.

Media Contact
Company Name: 2 Guys With Knives
Contact Person: Karla V Peniche
Email: Send Email
Phone: +1 778-828-9478
Address:9253 Shaughnessy St
City: Vancouver
State: British Columbia V6P 6R4
Country: Canada
Website: https://2guyswithknives.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: High Protein Meal Plan Vancouver: 2 Guys With Knives Delivers Structured Nutrition for Performance

The Invisible Thread: Tracing the Origin and Evolution of Bluetooth Technology

In the modern era of hyper-connectivity, we often take for granted the invisible signals weaving through our homes, offices, and industrial hubs. We tap a button, and our music plays; we walk into a room, and our smart lights adjust. At the heart of this seamless experience lies a protocol that has become a global standard: Bluetooth.

But for those navigating the complex world of the Internet of Things (IoT) or simply curious about the history of their devices, a fundamental question often arises: When was Bluetooth invented, and how did it transform from a niche cable-replacement project into the backbone of modern wireless communication?

The Birth of a Wireless Vision (1989–1994)

The history of Bluetooth doesn’t begin with a finished product, but with a problem. In the late 1980s, the computing world was a mess of proprietary cables. Nils Rydbeck, the Chief Technology Officer at Ericsson Mobile in Lund, Sweden, envisioned a “short-link” radio technology that could connect personal computers to wireless headsets.

In 1994, the project gained significant momentum when Ericsson’s Dr. Jaap Haartsen and Sven Mattisson developed the first viable architecture. Their goal was ambitious: create a low-power, low-cost radio interface that could replace the RS-232 serial data cables cluttering desks at the time.

The name itself, “Bluetooth,” was proposed in 1997 by Jim Kardach of Intel. He had been reading Frans G. Bengtsson’s historical novel The Long Ships about Vikings and King Harald “Bluetooth” Gormsson. Just as the King was famous for uniting Scandinavia, this new technology was intended to unite the PC and cellular industries with a short-range wireless link.

The Special Interest Group (SIG) and Global Standardization

While the tech was conceived in 1994, it wasn’t until 1998 that the Bluetooth Special Interest Group (SIG) was officially formed. This was a pivotal moment in tech history. Founding members including Ericsson, Intel, Nokia, Toshiba, and IBM realized that for the technology to succeed, it couldn’t belong to just one company. It needed to be a global, interoperable standard.

By 1999, the Bluetooth 1.0 specification was released. While revolutionary, these early days were fraught with “handshaking” difficulties and interference issues. However, the vision was clear: a universal language for devices to talk to one another without physical tethers.

From Audio to Automation: The Evolution of Versions

As the new millennium progressed, Bluetooth underwent several radical transformations to keep pace with the growing demands of data speed and energy efficiency.

The Classic Era

Early versions (1.0 to 3.0) focused primarily on data throughput. This era gave us the hands-free earpieces and wireless file transfers that defined mobile culture in the early 2000s. While effective, these “Classic” versions were power-hungry, requiring frequent charging for portable devices.

The Low Energy Revolution (BLE)

The most significant turning point for the Internet of Things occurred in 2010 with the introduction of Bluetooth 4.0, which included Bluetooth Low Energy (BLE). This wasn’t just an upgrade; it was a total redesign. BLE allowed devices to run for months or even years on a single coin-cell battery. This innovation opened the floodgates for wearable fitness trackers, medical monitors, and smart home sensors.

The Industrial Leap: Bluetooth 5.0 and Beyond

Released in 2016, Bluetooth 5.0 quadrupled the range, doubled the speed, and increased the broadcasting capacity by 800% compared to its predecessors. This allowed Bluetooth to move beyond the “personal area network” and into the realm of industrial automation and large-scale asset tracking.

The Modern Landscape: Bluetooth in the IoT Era

Today, we are seeing the fruition of the vision started in a Swedish laboratory in 1994. The technology has matured into a robust ecosystem capable of much more than just streaming audio.

In the industrial sector, Bluetooth has become the preferred choice for Indoor Positioning Systems (IPS) and Asset Management. Because modern Bluetooth hardware is so miniaturized and efficient, companies can now track inventory across massive warehouses with centimeter-level accuracy using “AoA” (Angle of Arrival) technology.

This is where the legacy of King Harald meets the cutting-edge manufacturing of today. Leading innovators in the hardware space, such as Minew, have taken these decades of protocol evolution and condensed them into specialized IoT modules, beacons, and sensors. By leveraging the latest Bluetooth 5.x standards, these hardware solutions provide the reliability and battery longevity that early 90s engineers could only dream of.

Why Bluetooth Won the Wireless War

Several technologies attempted to claim the short-range throne—Infrared (IrDA) required a direct line of sight, and early Wi-Fi was too taxing on batteries. Bluetooth won because of three key factors:

1. Interoperability: A Bluetooth device made in Japan works seamlessly with one made in Germany.

2. Adaptive Frequency Hopping (AFH): Bluetooth avoids interference by “hopping” between frequencies 1,600 times per second, ensuring stability even in “noisy” wireless environments.

3. Scalability: From a simple heart rate monitor to a complex mesh network of thousands of industrial lights, the protocol scales to meet the need.

The Future: Auracast and Beyond

As we look toward the future, the invention of Bluetooth continues to pay dividends. The recent introduction of Auracast™ broadcast audio is set to change how we engage with the world, allowing us to “tune in” to silent televisions in public spaces or join shared audio tours with our own devices.

Furthermore, the integration of Bluetooth into the “Matter” smart home standard ensures that the language started by Ericsson and Intel will remain the primary dialect of our homes for decades to come.

Conclusion

When we ask when was Bluetooth invented, we aren’t just looking for a date on a calendar; we are looking at the start of a movement toward a frictionless world. What began as a project to kill the RS-232 cable in 1994 has evolved into a sophisticated web of connectivity that powers our modern lives.

For businesses looking to integrate this history of innovation into their own operations, the choice of hardware is paramount. Utilizing professional-grade Minew Official Website | IoT Devices Manufacturer allows enterprises to harness these decades of development, ensuring their IoT deployments are as stable and efficient as the global standard demands.

The thread remains invisible, but its impact on our world has never been more visible.

Media Contact
Company Name: SHENZHEN MINEW TECHNOLOGIES CO., LTD.
Contact Person: Lawrence Zhan
Email: Send Email
Phone: 075521038160
Address:No.6, Qinglong Road, Longhua District
City: Shenzhen
State: Guangdong Sheng
Country: China
Website: https://www.minew.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Invisible Thread: Tracing the Origin and Evolution of Bluetooth Technology

London Makes History: 800 Devotees Gather for Second Shivohum Shiv Mela; City Witnesses Its First-ever Shiv Barat

London, United Kingdom – In a landmark moment for the Indian diaspora in Britain, the Sanatan Spirituality Foundation (SSF) hosted the second edition of the Shivohum Shiv Mela, drawing over 800 devotees and culminating in London’s first-ever Shiv Barat — the ceremonial recreation of Lord Shiva’s divine wedding procession. The sold-out festival has rapidly emerged as one of the most significant annual Sanatan gatherings in the United Kingdom.

The President of the Hindu Forum of Britain commended SSF for its contribution to preserving and celebrating Sanatan culture in Britain, while spiritual leaders from eight leading organizations praised the initiative for strengthening dharmic awareness among British Hindus. The evening opened with a sacred Rudra Abhishek and Jala Abhishek, coordinated by Vishal Bhardwaj, and conducted according to Vedic tradition by Shri Kiran Kumar, head priest of Wembley Temple. In an unbroken stream of devotion, 800 attendees offered water to the Shivlinga — a rare and deeply moving collective spiritual experience.

The cultural programme featured a powerful Bharatanatyam production choreographed by Guru Hausika Ji, in which young students brought to life episodes from the Shiv Purana, including the sacrifice of Sati and the rebirth of Mata Parvati. Another Odissi Tandav done by Utkalika group. The performance left many in the audience visibly emotional, underscoring the importance of transmitting Sanatan heritage to the next generation. The emotional crescendo arrived with the historic Shiv Barat, directed by Nimit Sishodia and anchored by Shri Ajay Prakash.

Characters portraying Brahmadev, Mata Saraswati, Bhagawan Vishnu, Mata Lakshmi, Mahadev and Mata Parvati entered in regal sequence, accompanied by Nandi, Bhakt-gana, Aghoris and Bhut-gana. As chants of “Har Har Mahadev” echoed across the hall, devotees — including families who have lived in Britain for decades — were seen in tears, describing the moment as a spiritual homecoming. The sight of children and teenagers chanting with pride and devotion emerged as one of the evening’s most powerful images. On this occasion Thandai was distributed by Sonu Sharma ji from SSF, reminding all about bharat.

The festival also hosted a Shiv Charcha, an inter-organizational dialogue on sustaining Dharma in contemporary Britain, featuring leaders from ISKCON, International Siddhashram, Brahma Kumaris, Brahma Rishi Mission, Divya Jyoti Jagrati Sansthan & Sri Jagannath Society UK. Addressing the gathering, Acharya Abhi Yogi, President of SSF, reaffirmed the foundation’s mission to empower young Sanatanis growing up in the UK with a living connection to their spiritual roots.

Offered entirely free of charge through collective community support and volunteer service by IDUK volunteers also, the evening concluded with an uplifting community bhajan jamming session with Geetika and the bhajan team. Through the second Shivohum Shiv Mela and London’s first Shiv Barat, Sanatan Spirituality Foundation has signaled a defining new chapter for Sanatan Dharma in Britain — a declaration that Hindu spiritual culture in the United Kingdom is vibrant, organized and flourishing.

Short Video for event: https://www.youtube.com/watch?v=wMjduR-ytv4

Youtube: www.youtube.com/@abhiyogishow

Facebook: www.facebook.com/ssfconnect

Instagram: www.instagram.com/ssfconnect

About SSF

The Sanatan Spirituality Foundation is a global organization dedicated to the revival and propagation of Sanatan spiritual wisdom through festivals, workshops, meditation programmes and community engagement initiatives worldwide.

More info: www.sanatanspirituality.org

Media Contact
Company Name: Sanatan Spirituality Foundation
Contact Person: Shri Ajay Prakash
Email: Send Email
City: London
Country: United Kingdom
Website: www.sanatanspirituality.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: London Makes History: 800 Devotees Gather for Second Shivohum Shiv Mela; City Witnesses Its First-ever Shiv Barat

Aaron Johnson Featured in America Inspire Magazine’s Volume 8, Issue 11 Special Edition

America Inspire Magazine highlights author Aaron Johnson and his book Don’t Be A Dumb Jock, exploring education, responsibility, and independence.

America Inspire Magazine launches its Volume 8, Issue 11 Special Edition, featuring a dedicated editorial focus on author Aaron Johnson, a writer whose work speaks to athletes, parents, coaches, and readers seeking a more intentional approach to life, discipline, and long-term success. This special edition continues the magazine’s mission of highlighting voices that encourage growth, accountability, and meaningful contribution to society.

At the center of this issue is Johnson’s book, Don’t Be A Dumb Jock: How To Be A Super Human Being: Why Education, Social Responsibility and Financial Independence Go Hand and Ball, a concise yet impactful guide designed for readers ages 13 and up, regardless of athletic background.

The book is available for purchase on Amazon.

It is also available in the audiobook format: https://a.co/d/0felACVu

The audiobook arrives at a time when athletes carry more cultural influence than ever before. With social media giving athletes a platform to reach millions, Johnson argues that this power comes with responsibility. Don’t Be A Dumb Jock equips readers with the mindset to leverage that influence for education, financial independence, and social responsibility.

This new audiobook format ensures its powerful message reaches an even broader audience of athletes, parents, coaches, and anyone striving to live their best life.

A Book Written for Athletes, and for Life

In Don’t Be A Dumb Jock, Aaron Johnson addresses a reality often overlooked in sports culture: athletic careers are temporary, but personal responsibility, education, and self-awareness last a lifetime. The book presents an opportunity for learning before an athlete’s sports journey ends and the next chapter of life begins.

Written for both athletes and non-athletes, the book emphasizes that individuals often “do not know what they do not know” until experience provides clarity. Johnson challenges readers to gain that understanding earlier by developing physical discipline, mental strength, and emotional awareness; qualities that elevate human potential at any stage of life.

Rather than focusing solely on competition, the book reframes sports as a training ground for life itself, where habits formed through exercise, teamwork, and discipline can translate into long-term personal empowerment.

The Concept of the “Super Human Being”

A central theme of the book is Johnson’s concept of the “Super Human Being.” He explores how physical fitness, mental resilience, and emotional intelligence combine to increase an individual’s influence and responsibility in the modern world.

With the rise of social media, athletes now have platforms larger than ever before. Johnson emphasizes that visibility comes with accountability, as people often follow athletes’ choices, words, and actions. The book encourages readers to recognize this influence and use it responsibly, whether on the field, online, or within their communities.

While rooted in athletic experience, the message extends far beyond sports. The book positions personal growth, purpose, and discipline as universal tools that help individuals maximize both passion and potential, regardless of profession or background.

Why America Inspire Magazine Selected Aaron Johnson

America Inspire Magazine carefully curates its special edition features to reflect voices that align with values of self-improvement, social responsibility, and inspiration. Aaron Johnson was selected for Volume 8, Issue 11 due to his clear, direct approach to addressing life preparation, especially for young athletes navigating identity, influence, and future independence.

His work speaks to parents and coaches seeking guidance for the next generation, while also resonating with readers who recognize that personal development does not end with youth or athletic participation. By emphasizing education, responsibility, and financial independence alongside physical discipline, Johnson’s book aligns with the magazine’s focus on holistic human growth.

Publication and Product Details

Don’t Be A Dumb Jock: How To Be A Super Human Being was published on July 11, 2018, by CreateSpace Independent Publishing Platform. The book is written in English and spans 94 pages, offering a focused and accessible reading experience.

ISBN-13: 979-8295580239

Item Weight: 5.7 ounces

Dimensions: 5.5 x 0.23 x 8.5 inches

The book has received strong reader feedback, earning an average rating of 4.9 out of 5 stars from verified customer reviews. It continues to be recommended for current athletes, aspiring athletes, parents, and mentors who want to encourage long-term thinking beyond sports performance.

To learn more about Aaron Johnson, visit the official website https://aaronjohnsonfitnessclub.com/

Inspiring Athletes, Parents, and the Next Generation

As featured in America Inspire Magazine – Volume 8, Issue 11 Special Edition, Aaron Johnson’s work serves as a reminder that discipline, awareness, and responsibility are transferable skills that shape success long after the final whistle blows.

Through Don’t Be A Dumb Jock, Johnson invites readers to rethink what it truly means to succeed; not just as athletes, but as complete human beings equipped to navigate life with purpose, influence, and integrity.

Media Contact
Company Name: America Inspire Mag
Contact Person: Support
Email: Send Email
Country: United States
Website: americainspiremag.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aaron Johnson Featured in America Inspire Magazine’s Volume 8, Issue 11 Special Edition

Biliary Tract Cancer Market: Expanding Revenue Landscape to 2034 – DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai, Merck

The Key Biliary Tract Cancer Companies in the market include – Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others.

 

DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Biliary Tract Cancer Market Report:

https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market

 

Some of the key facts of the Biliary Tract Cancer Market Report:

  • The Biliary Tract Cancer market size is anticipated to grow with a significant CAGR during the study period (2020–2034).

  • In January 2026, Summit Therapeutics Inc. (NASDAQ: SMMT) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) treatment. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026. In parallel, Akeso is advancing multiple Phase III clinical trials of ivonescimab beyond NSCLC, including studies in biliary tract, colorectal, breast, pancreatic, small cell lung, and head and neck cancers.

  • In September 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has received CE IVDR approval for two label extensions of its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. HER2, a receptor protein expressed in multiple cancers, acts as a predictive biomarker to determine a patient’s eligibility for HER2-targeted therapies. The VENTANA HER2 (4B5) test is the first and only companion diagnostic approved to identify HR-positive metastatic breast cancer patients with HER2-ultralow expression. Such patients may qualify for treatment with ENHERTU® (trastuzumab deruxtecan), a specially designed HER2-directed antibody-drug conjugate (ADC) developed by Daiichi Sankyo and co-developed and commercialized with AstraZeneca.

  • In April 2025, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company specializing in oncology and antibody-based therapies, reported that its ongoing Phase 2/3 COMPANION-002 trial evaluating tovecimig (previously CTX-009) in combination with paclitaxel for advanced biliary tract cancer (BTC) met the primary efficacy endpoint with statistically significant top-line results.

  • In January 2025, The Phase 3 SWOG S1815 trial (NCT03768414) revealed that adding nab-paclitaxel (Abraxane) to the standard chemotherapy regimen of gemcitabine and cisplatin did not lead to a statistically significant improvement in overall survival (OS) or progression-free survival (PFS) compared to gemcitabine and cisplatin alone in patients with newly diagnosed advanced biliary tract cancer.

  • In December 2024, Jazz Pharmaceuticals announced that the U.S. FDA has granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL for intravenous administration. This approval is for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC), confirmed by an FDA-approved test.

  • In November 2024, CTX-009 is a bispecific antibody that targets both Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), two pathways crucial for angiogenesis and tumor vascularization. Preclinical and early clinical data suggest that inhibiting both pathways offers strong anti-tumor effects across various solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Partial responses have been observed in heavily pre-treated cancer patients who were resistant to approved anti-VEGF therapies. The COMPANION-002 trial, a Phase 2/3 study, is evaluating the combination of CTX-009 and paclitaxel versus paclitaxel alone in patients with previously treated, advanced metastatic or recurrent biliary tract cancers (BTC). Clinical trial information: NCT05506943.

  • In August 2024, Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology and developing proprietary antibody-based therapeutics for various diseases, today announced the completion of patient enrollment in its COMPANION-002 trial. The trial, a randomized Phase 2/3 study, involves 150 patients and evaluates CTX-009 in individuals with biliary tract cancer (BTC).

  • In June 2024, Bold Therapeutics, a global leader in the development of innovative metallotherapeutics, announced positive Phase 2 safety and efficacy results for its lead asset, BOLD-100, in the treatment of advanced metastatic biliary tract cancer (BTC) and gastric cancer (GC) at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

  • Chemotherapy regimens currently dominate the market. However, several promising therapies in development, such as CX-4945 and CTX-009, are anticipated to significantly impact the Biliary Tract Cancer treatment landscape during the forecast period (2024–2034).

  • In 2023, the United States held the largest share of the Biliary Tract Cancer market in the 7MM, representing nearly 48% of the market, compared to the EU4, the UK, and Japan.

  • In 2023, the United States represented approximately 30% of the total incident cases of Biliary Tract Cancer in the 7MM, accounting for the highest number of cases within this region.

  • In the United States, the majority of Biliary Tract Cancer cases occur in individuals aged 70–79 years, accounting for approximately 30% of all age-specific cases.

  • In the United States, TP53 mutations were the most prevalent among mutation-specific cases of Biliary Tract Cancer in 2023, followed by KRAS mutations.

  • Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others

  • Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others

  • The Biliary Tract Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Tract Cancer pipeline products will significantly revolutionize the Biliary Tract Cancer market dynamics.

 

Biliary Tract Cancer Overview

Biliary Tract Cancer (BTC) is a rare and aggressive cancer that originates in the bile ducts, which are responsible for carrying bile from the liver to the small intestine. It includes cancers of the bile ducts inside and outside the liver, as well as the gallbladder. Symptoms can be vague and may include jaundice, abdominal pain, and weight loss, often leading to delayed diagnosis. BTC is typically diagnosed in later stages, making treatment more challenging. Treatment options may include surgery, chemotherapy, and targeted therapies, depending on the cancer’s location and stage.

 

To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tract Cancer Market Forecast

 

Biliary Tract Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Biliary Tract Cancer Epidemiology Segmentation:

The Biliary Tract Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Biliary Tract Cancer

  • Prevalent Cases of Biliary Tract Cancer by severity

  • Gender-specific Prevalence of Biliary Tract Cancer

  • Diagnosed Cases of Episodic and Chronic Biliary Tract Cancer

 

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ Biliary Tract Cancer Epidemiology Forecast

 

Biliary Tract Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tract Cancer market or expected to get launched during the study period. The analysis covers Biliary Tract Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Biliary Tract Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Biliary Tract Cancer Therapies and Key Companies

  • Keytruda (pembrolizumab): Merck Sharp & Dohme

  • Imfinzi (durvalumab): AstraZeneca

  • Futibatinib (TAS-120): Taiho Oncology

  • Melphalan: Delcath Systems

  • E7090 (tasurgratinib): Eisai

  • TT-00420: TransThera Sciences (Nanjing)

  • ARQ 087 (Derazantinib): Basilea Pharmaceutica

  • Lenvima (lenvatinib): Eisai and Merck & Co

  • Zanidatamab: Zymeworks and BeiGene

  • XmAb20717: Xencor, Inc.

  • Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.

  • CTX-009: Compass Therapeutics

  • MEDI5752: AstraZeneca

  • Brigimadlin: Boehringer Ingelheim

  • ZB131: ZielBio, Inc.

  • GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.

  • BNT141: BioNTech SE

  • SO-C101: SOTIO Biotech

  • CT-0508: Carisma Therapeutics Inc

  • RAIN-32: Rain Oncology Inc

  • AVA6000: Avacta Life Sciences Ltd

  • DB-1303: DualityBio Inc.

 

Discover more about therapies set to grab major Biliary Tract Cancer market share @ Biliary Tract Cancer Treatment Market

 

Biliary Tract Cancer Market Drivers

  • Rising incidence of biliary tract cancers globally, particularly cholangiocarcinoma, driven by aging populations and lifestyle risk factors.

  • High unmet medical need due to late-stage diagnosis and limited effectiveness of conventional chemotherapy.

  • Advancements in molecular profiling enabling targeted therapies and precision oncology approaches.

  • Increasing R&D investments and growing clinical trial activity focused on immunotherapies and targeted agents.

  • Regulatory incentives such as orphan drug designation and fast-track approvals supporting innovation.

 

Biliary Tract Cancer Market Barriers

  • Late diagnosis and disease heterogeneity complicating patient stratification and treatment outcomes.

  • Limited availability of approved therapies, especially in earlier lines of treatment.

  • High development and treatment costs restricting patient access and reimbursement.

  • Challenges in conducting large-scale clinical trials due to low prevalence and geographic variability.

  • Safety concerns and modest response rates associated with current treatment options.

 

Scope of the Biliary Tract Cancer Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others

  • Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others

  • Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies

  • Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Biliary Tract Cancer Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement

 

To know more about Biliary Tract Cancer companies working in the treatment market, visit @ Biliary Tract Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Biliary Tract Cancer Market Report Introduction

2. Executive Summary for Biliary Tract Cancer

3. SWOT analysis of Biliary Tract Cancer

4. Biliary Tract Cancer Patient Share (%) Overview at a Glance

5. Biliary Tract Cancer Market Overview at a Glance

6. Biliary Tract Cancer Disease Background and Overview

7. Biliary Tract Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Biliary Tract Cancer

9. Biliary Tract Cancer Current Treatment and Medical Practices

10. Biliary Tract Cancer Unmet Needs

11. Biliary Tract Cancer Emerging Therapies

12. Biliary Tract Cancer Market Outlook

13. Country-Wise Biliary Tract Cancer Market Analysis (2020–2034)

14. Biliary Tract Cancer Market Access and Reimbursement of Therapies

15. Biliary Tract Cancer Market Drivers

16. Biliary Tract Cancer Market Barriers

17. Biliary Tract Cancer Appendix

18. Biliary Tract Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tract Cancer Market: Expanding Revenue Landscape to 2034 – DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai, Merck